Companies / Health Care / Biotechnology
Biogen stock buybacks
BIIB—No share repurchases in the company’s standard SEC financial data for the last twelve months.
Biogen’s filings haven’t reported share repurchases in standard form since Q4 2023.
Show as table
| Period | Value |
|---|---|
| Q2 '20 | $2.8B |
| Q3 '20 | $1.3B |
| Q4 '20 | $400M |
| Q1 '21 | $600M |
| Q2 '21 | $450M |
| Q3 '21 | $750M |
| Q4 '21 | $0 |
| Q1 '22 | $0 |
| Q2 '22 | $500M |
| Q3 '22 | $250M |
| Q4 '22 | $0 |
| Q1 '23 | $0 |
| Q2 '23 | $0 |
| Q3 '23 | $0 |
| Q4 '23 | $0 |
| Q1 '24 | $0 |
| Q2 '24 | $0 |
| Q3 '24 | $0 |
| Q4 '24 | $0 |
| Q1 '25 | $0 |
| Q2 '25 | $0 |
| Q3 '25 | $0 |
| Q4 '25 | $0 |
| Q1 '26 | $0 |
Show as table
| Period | Value |
|---|---|
| Q2 '20 | 160.9M |
| Q3 '20 | 157.2M |
| Q4 '20 | 154.0M |
| Q1 '21 | 152.3M |
| Q2 '21 | 150.1M |
| Q3 '21 | 148.6M |
| Q4 '21 | 147.4M |
| Q1 '22 | 147.6M |
| Q2 '22 | 146.2M |
| Q3 '22 | 144.8M |
| Q4 '22 | 145.4M |
| Q1 '23 | 145.2M |
| Q2 '23 | 145.5M |
| Q3 '23 | 144.8M |
| Q4 '23 | 146.9M |
| Q1 '24 | 145.9M |
| Q2 '24 | 145.9M |
| Q3 '24 | 146.1M |
| Q4 '24 | 145.7M |
| Q1 '25 | 146.6M |
| Q2 '25 | 146.7M |
| Q3 '25 | 147.1M |
| Q4 '25 | 148.0M |
| Q1 '26 | 148.4M |
$0last quarter (Q1 2026)
−$294Mnet of stock compensation ($294M)
+1.2%diluted shares, 1 year
−8.8%diluted shares, 5 years
—dividends, 12 months
0%of free cash flow ($2.4B) spent on buybacks
$0raised by issuing stock, 12 months
147.6Mshares outstanding (Apr 27, 2026)
Biogen’s 10-Q for the period ending Jun 30, 2026 (filed Jul 29, 2026) isn’t in the SEC’s structured data yet, so figures here run through Mar 31, 2026. Read the new filing.
Biogen’s recent filings don’t report repurchases in the standard XBRL fields we read. That usually means it didn’t buy back stock, but some companies report buybacks only in custom fields. Check its latest 10-Q to be sure.
By fiscal year
Questions
- Does Biogen buy back its stock?
- Biogen’s filings haven’t reported share repurchases in standard form since Q4 2023.
- How much did Biogen spend on buybacks in fiscal 2024?
- $0, according to its 10-K for the fiscal year ending Dec 31, 2024.
- Is Biogen's share count going down?
- Its diluted share count changed −8.8% over five fiscal years and +1.2% over the last year.
Latest filing used: 10-Q for the period ending Jun 30, 2026, filed Jul 29, 2026 · open on SEC.gov